Aquestive Therapeutics (AQST) EV to CFO (2018 - 2026)

Aquestive Therapeutics has reported EV to CFO for 9 years, with the latest figure at 44.87 in Q2 2026.

• On a quarterly basis, EV to CFO fell 32.35% year-over-year to 44.87 in Q2 2026; TTM through Jun 2026 was 9.34, a 72.91% decrease from a year earlier, with the FY2025 full-year figure at 12.73, down 79.24% from the prior year.
• EV to CFO was 44.87 for Q2 2026 at Aquestive Therapeutics, down from 27.36 in the prior quarter.
• The five-year high for EV to CFO was 15.79 in Q3 2022, with the low at 78.79 in Q4 2025.
• Average EV to CFO over 5 years is 22.4, with a median of 22.11 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EV to CFO surged 199.69% in 2022, then plunged 979.33% in 2023.
• Over 5 years, EV to CFO stood at 2.64 in 2022, then tumbled by 979.33% to 23.18 in 2023, then sank by 68.78% to 39.13 in 2024, then slumped by 101.37% to 78.79 in 2025, then jumped by 43.05% to 44.87 in 2026.
• The last three EV to CFO figures came in at 44.87 (Q2 2026), 27.36 (Q1 2026), and 78.79 (Q4 2025), per Business Quant data.